1. Home
  2. ZCMD vs CDT Comparison

ZCMD vs CDT Comparison

Compare ZCMD & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zhongchao Inc.

ZCMD

Zhongchao Inc.

HOLD

Current Price

$1.10

Market Cap

2.0M

Sector

Real Estate

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$3.50

Market Cap

2.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZCMD
CDT
Founded
2012
2019
Country
China
United States
Employees
N/A
4
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
2.4M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
ZCMD
CDT
Price
$1.10
$3.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.7M
133.2K
Earning Date
04-28-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.02
$0.30
52 Week High
$11.96
$11.00

Technical Indicators

Market Signals
Indicator
ZCMD
CDT
Relative Strength Index (RSI) 46.61 64.00
Support Level $0.75 $2.57
Resistance Level $2.70 $3.90
Average True Range (ATR) 1.14 0.42
MACD -0.10 0.06
Stochastic Oscillator 0.73 51.09

Price Performance

Historical Comparison
ZCMD
CDT

About ZCMD Zhongchao Inc.

ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.

Share on Social Networks: